DVA

Business profile & competitive position

DaVita Inc. operates in the Healthcare sector, specifically in the Medical - Care Facilities industry. Its core business is kidney dialysis: as of December 31, 2025, the company ran 2,657 outpatient dialysis centers in the United States serving roughly 200,500 patients, plus an international footprint of 585 outpatient centers across 14 countries serving approximately 94,500 patients. The care mix spans outpatient hemodialysis, hospital inpatient dialysis, home-based dialysis, laboratory services, kidney transplant support, and integrated kidney care services.

The financial signature of this model is a 6.5% net margin paired with a -133.2% return on equity. A positive net margin shows the clinic-level operations are profitable, while the deeply negative ROE almost always points to a thin or negative equity base rather than operating losses—often the result of debt, share repurchases, or lease-heavy capital structures common in scaled facility operators. Scale is the clearest competitive feature: DaVita has led CMS’s Quality Incentive Program for the 11 most recently reported years and the Five-Star Quality Rating System for 10. That said, concentration is also a structural vulnerability. The 10-K notes U.S. dialysis made up about 86% of consolidated revenue, and nearly all non-hospital dialysis profit came from commercial payors. A high reliance on a single service line and a narrow commercial-insurer profit pool means the moat is durable but not unassailable.

Financial posture

DaVita currently carries an $11.7 billion market cap and trades at a 14.2x price-to-earnings multiple. The stock’s beta is 0.80, which is consistent with a defensive, non-cyclical healthcare service provider. At the current snapshot price of $185.575, the 50-day exponential moving average is $185.51, so price is essentially parked on top of its short-term trend, while a 52.5 RSI reading sits in neutral territory.

A 6.5% net margin is modest for a business that depends on fixed clinic assets and labor-heavy service delivery. The -133.2% ROE stands out as the dominant financial tension: earnings are positive but equity is clearly thin, which is why ROE reads as strongly negative. For investors evaluating posture, the takeaway is that DaVita’s valuation—14.2x earnings—reflects a market discount for balance-sheet leverage, payor concentration, and policy risk rather than pure earnings quality. The low beta offers relative stability, but the leverage profile and margin structure mean the company is more rate-sensitive and debt-dependent than the average care facility name.

Strategic priorities & outlook

In its most recent 10-K, DaVita laid out three operational priorities. First, it wants to “reimagine” kidney care so that it is more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities across the entire renal continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. Third, it is supporting CMS’s Comprehensive Kidney Care Contracting model goals: delaying disease progression, promoting home dialysis when clinically appropriate, and incentivizing transplants.

These priorities tie directly to the revenue mix. With U.S. dialysis at roughly 86% of consolidated revenue, growth increasingly depends on moving upstream into chronic kidney disease management and downstream into transplant support, while also shifting site of care toward home dialysis. The integrated kidney care segment is already showing up in results, as third-party reports flag “IKC strength” as a driver of the most recent quarterly beat. International diversification—585 centers serving 94,500 patients—adds geographic optionality, but the profit engine remains the United States.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita’s macro exposure is dominated by regulation and reimbursement rather than traditional business-cycle risk. Medicare and Medicaid rates, the ESRD bundled payment system, and value-based care pilots such as the Integrated Kidney Care Contracting model directly determine pricing and profitability. Any change in CMS reimbursement rates, coverage rules, or quality benchmarks can alter cash flow faster than volume changes.

Labor is the other macro pressure point. Dialysis clinics require specialized nurses, technicians, and patient-care staff; wage inflation and staffing shortages affect sector margins broadly. Supply-chain exposure centers on dialyzers, concentrates, and anemia-management pharmaceuticals used in routine dialysis. On the international side, the 14-country footprint creates foreign-exchange and localized regulatory risk. Overall, the industry’s key sensitivities are policy, payor mix, labor cost, and medical supply availability—not commodity cycles or consumer discretionary demand.

Recent developments

The most recent news cluster centers on the third-quarter 2026 report, released on October 29, 2026:

• October 30, 2026 (Zacks): “DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y.”
• October 30, 2026 (MarketBeat): “What DaVita (DVA) Said on Its Q3 Earnings Call.”
• October 29, 2026 (Seeking Alpha): “DaVita Inc. (DVA) Q3 2026 Earnings Call Transcript.”
• October 29, 2026 (Zacks): “DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates.”

The actual numbers matched the headline tone: EPS came in at $3.82, beating the $3.57 estimate by 7%. Despite the beat, the stock fell 3.01% the next trading session and recorded a null 5-day drift. That reaction reinforces that headline beats are not automatically bullish events; forward guidance, reimbursement commentary, and commercial payor mix often matter more than the bottom-line surprise.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten the market’s official estimate seven times, for an 88% beat rate. The average earnings surprise over that window is 3.8%. More importantly, the average 5-day price move following those reports is 9.9% to the upside, which the dataset classifies as an “up” post-earnings drift.

The last four quarters show how lumpy that drift can be. The most recent report on October 29, 2026 was a 7% beat but produced a -3.01% next-day move and a flat 5-day drift. The August 4, 2026 quarter was a 3.6% beat yet the stock plunged 17.24% the next day and 21.78% over the following five days. By contrast, the May 5, 2026 report delivered a 19.1% beat and sparked a 23.46% one-day gain and a 27.7% five-day gain. The February 2, 2026 quarter posted a 4.9% beat with a 21.17% next-day move and a 23.79% five-day move.

So the historical pattern is a high beat rate and a positive average post-earnings drift, but the dispersion is extreme. A trader tracking the name should not confuse the 9.9% average upside drift with predictability; the range runs from roughly -21.8% to +27.7%. The next scheduled report is February 1, 2027 after the close, with a consensus EPS estimate of $4.26.

For a deeper dive into how sell-side and institutional models are interpreting DaVita’s leverage profile, payor mix, and upcoming February 2027 earnings setup, review the full institutional verdict on the ticker.